Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
复制标题
DOI：
10.1007/s00198-010-1379-y
复制
发表时间：
2011-06
影响因子：
4
通讯作者：
Eastell, R.
中科院分区：
文献类型：
--
作者：
Blumsohn, A.;Marin, F.;Nickelsen, T.;Brixen, K.;Sigurdsson, G.;Gonzalez de la Vera, J.;Boonen, S.;Liu-Leage, S.;Barker, C.;Eastell, R.
我们报告了患有骨质疏松症的绝经后女性根据之前的抗骨吸收治疗，在特立帕肽治疗的前 6 个月内骨形成生化标志物的变化。既往治疗不会对特立帕肽治疗的反应产生不利影响。治疗 6 个月后可达到类似的骨标志物水平。对于既往接受过骨质疏松药物治疗的受试者，特立帕肽治疗对骨转换生化标志物的反应尚未完全阐明。我们检查了接受特立帕肽治疗的骨质疏松症女性的骨形成生化标志物，并确定：(1) 该反应是否与先前的骨质疏松症治疗相关，(2) 哪种标志物显示出检测治疗反应的最佳性能，以及 (3) 骨标志物的早期变化与特立帕肽治疗 24 个月后随后的骨矿物质密度 (BMD) 变化之间的相关性。我们在 10 个国家的 95 个中心对 758 名患有骨质疏松症的绝经后妇女（其中 181 名未接受过治疗）进行了一项为期 24 个月的前瞻性、开放标签研究，这些妇女至少进行了一项基线后骨标志物测定。服用特立帕肽（20 微克/天）长达 24 个月。我们测量了基线、第 1 个月和第 6 个月时的 I 型前胶原 N 末端前肽 (PINP)、骨特异性碱性磷酸酶 (b-ALP) 和总碱性磷酸酶 (t-ALP)，以及腰椎、全髋和股骨颈从基线到 24 个月的 BMD 变化。无论之前是否进行过骨质疏松症治疗，服用特立帕肽 1 个月后，形成标志物都会显着增加。与未接受治疗的患者相比，先前接受过治疗的患者 1 个月时的绝对增长较低，但 6 个月后，所有组都达到了相似的水平。 PINP 显示出最佳的信噪比。基线 PINP 与 24 个月时的 BMD 反应呈显着正相关。这项研究表明，先前接受抗骨吸收药物治疗的受试者中，骨形成标志物对特立帕肽的长期反应性不受影响。
We report the changes in biochemical markers of bone formation during the first 6 months of teriparatide therapy in postmenopausal women with osteoporosis according to previous antiresorptive treatment. Prior therapy does not adversely affect the response to teriparatide treatment. Similar bone markers levels are reached after 6 months of treatment. The response of biochemical markers of bone turnover with teriparatide therapy in subjects who have previously received osteoporosis drugs is not fully elucidated. We examined biochemical markers of bone formation in women with osteoporosis treated with teriparatide and determined: (1) whether the response is associated with prior osteoporosis therapy, (2) which marker shows the best performance for detecting a response to therapy, and (3) the correlations between early changes in bone markers and subsequent bone mineral density (BMD) changes after 24 months of teriparatide. We conducted a prospective, open-label, 24-month study at 95 centers in 10 countries in 758 postmenopausal women with established osteoporosis (n = 181 treatment-naïve) who had at least one post-baseline bone marker determination. Teriparatide (20 μg/day) was administered for up to 24 months. We measured procollagen type I N-terminal propeptide (PINP), bone-specific alkaline phosphatase (b-ALP), and total alkaline phosphatase (t-ALP) at baseline, 1 and 6 months, and change in BMD at the lumbar spine, total hip and femoral neck from baseline to 24 months. Significant increases in formation markers occurred after 1 month of teriparatide regardless of prior osteoporosis therapy. The absolute increase at 1 month was lower in previously treated versus treatment-naïve patients, but after 6 months all groups reached similar levels. PINP showed the best signal-to-noise ratio. Baseline PINP correlated positively and significantly with BMD response at 24 months. This study suggests that the long-term responsiveness of bone formation markers to teriparatide is not affected in subjects previously treated with antiresorptive drugs.
登录
查看更多内容
影响因子：
158.5
作者：
Cosman, F;Nieves, J;Lindsay, R
通讯作者：
Lindsay, R
影响因子：
158.5
作者：
Finkelstein, JS;Hayes, A;Neer, RM
通讯作者：
Neer, RM
影响因子：
5.8
作者：
Bauer, DC;Garnero, P;Black, DM
通讯作者：
Black, DM
影响因子：
6.2
作者：
Ma, Yanfei L.;Zeng, Qingqiang;Eriksen, Erik Fink
通讯作者：
Eriksen, Erik Fink
影响因子：
5.8
作者：
Miller, Paul D.;Delmas, Pierre D.;Bilezikian, John P.
通讯作者：
Bilezikian, John P.